Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085814 | 0.99 | PTGS2 (0.42) | PTGS2PTPN1TRPV1HSD17B10MEN1 | |
| SCHEMBL2086485 | 0.92 | PTGS2 (0.42) | PTGS2PTPN1FAAHHPGD | |
| SCHEMBL2085985 | 0.92 | PTGS2 (0.43) | PTGS2PTPN1FAAHHPGD | |
| SCHEMBL2085085 | 0.91 | CYP1A2 (0.41) | PTGS2FAAH | |
| SCHEMBL2085577 | 0.91 | PTGS2 (0.43) | PTGS2PTPN1FAAH | |
| SCHEMBL2083265 | 0.90 | PTPN1 (0.39) | PTGS2PTPN1FAAHHPGD | |
| SCHEMBL2085311 | 0.90 | PTPN1 (0.38) | PTGS2PTPN1FAAHHPGD | |
| SCHEMBL2085477 | 0.90 | CNR1 (0.38) | PTGS2PTPN1FAAHHPGD | |
| SCHEMBL2085545 | 0.90 | CNR1 (0.40) | PTGS2PTPN1FAAH | |
| SCHEMBL2084596 | 0.90 | PTPN1 (0.39) | PTGS2PTPN1FAAHHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863332-B2 | Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-04 | — | — | US | disclosed |
| EP-1781297-B1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-10-15 | — | — | EP | disclosed |
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-13 | — | — | US | disclosed |
| EP-1781297-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018326-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PTGS2 625/4885PTPN1 1201/4885TRPV1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.